HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Walmart Exceeds Priority Chemical Reduction Targets

Executive Summary

Walmart Inc., which aimed for a 10% reduction in use of priority chemicals in beauty, personal care and household cleaning products sold in stores by 2022, is years ahead of its goal.

You may also be interested in...



Walmart Sustainable Chemistry Policy A “Big Deal,” But Raises Questions

While generally seen as a positive step promoting ingredient disclosure and safer products, Walmart’s Policy for Sustainable Chemistry in Consumables raises questions among consumer advocates. The Campaign for Safe Cosmetics wants the mega-retailer to release its list of “high-priority” chemicals publicly and seeks clarification on how the policy will enable more informed decisions by shoppers.

Industry Suggests NIH Office Of Dietary Supplements Get More Current, Collaborative

Industry comments on NIH ODS strategic plan focus on persuading it to give trade associations input on its activities, specifically for fact sheets on dietary supplement topics. Stakeholders also want more dialogue with ODS and opportunity to comment on initiatives.

CHPA Urges NIH Office of Dietary Supplements To ‘Educate’ Congress, FDA On Label Database

With Congress considering mandatory supplement product listing as requested by FDA, trade group asks NIH’s Office of Dietary Supplements to share its experience building and maintaining its label database.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel